CVRx (NASDAQ:CVRX) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of CVRx (NASDAQ:CVRX) from a hold rating to a sell rating in a research report released on Saturday morning.

CVRX has been the subject of several other research reports. Craig Hallum cut CVRx from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a research report on Friday. Lake Street Capital cut CVRx from a “buy” rating to a “hold” rating and set a $3.50 price target on the stock. in a report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research note on Monday, August 3rd. Piper Sandler lowered shares of CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price objective for the company. in a report on Friday. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $10.00 price objective on shares of CVRx in a research report on Tuesday, April 14th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, CVRx presently has a consensus rating of “Hold” and a consensus target price of $6.90.

CVRx Trading Down 59.8%

Shares of CVRx stock opened at $2.39 on Friday. The company has a market capitalization of $63.43 million, a P/E ratio of -1.21 and a beta of 0.81. The company has a debt-to-equity ratio of 2.01, a quick ratio of 8.89 and a current ratio of 10.20. The company has a fifty day moving average of $5.19 and a 200 day moving average of $6.49. CVRx has a fifty-two week low of $2.30 and a fifty-two week high of $11.30.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.01). CVRx had a negative return on equity of 133.84% and a negative net margin of 84.93%.The business had revenue of $15.71 million during the quarter, compared to analysts’ expectations of $15.55 million. On average, sell-side analysts anticipate that CVRx will post -1.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CVRx

A number of hedge funds have recently made changes to their positions in CVRX. Johnson & Johnson purchased a new position in shares of CVRx in the second quarter valued at $20,687,786,000. BlackRock Inc. bought a new position in CVRx during the second quarter valued at $6,402,000. GSK plc bought a new position in CVRx during the fourth quarter valued at $7,154,000. Royal Bank of Canada grew its stake in shares of CVRx by 6,559.3% in the 1st quarter. Royal Bank of Canada now owns 706,950 shares of the company’s stock worth $6,688,000 after buying an additional 696,334 shares in the last quarter. Finally, Balyasny Asset Management L.P. increased its holdings in shares of CVRx by 65.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 674,685 shares of the company’s stock worth $3,967,000 after buying an additional 267,063 shares during the last quarter. 75.27% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting CVRx

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: CVRx reported second-quarter revenue of $15.71 million, slightly above the $15.55 million analyst consensus. Its per-share loss of $0.53 was also an improvement from a $0.57 loss a year earlier, although it narrowly missed the $0.52 consensus loss. CVRx Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Despite downgrading the shares to “hold,” Lake Street Capital and Craig Hallum set price targets of $3.50 and $4.00, respectively—above the current trading level—suggesting potential recovery if execution improves. The Fly analyst ratings
• Neutral Sentiment: Johnson Fistel said it is investigating whether CVRx or certain executives violated securities laws in connection with the guidance reduction and sales-execution disclosures. The announcement is an investigation notice, not a finding of wrongdoing, but it adds headline and legal risk. Johnson Fistel investigation notice
• Negative Sentiment: CVRx cut third-quarter revenue guidance to $13.5 million-$14.5 million, well below the $16.9 million consensus, and reduced full-year 2026 revenue guidance to $58 million-$60 million from an implied level near the $65.4 million consensus. Management cited slower sales productivity and Medicare Advantage-related headwinds. CVRx forecasts 2026 revenue
• Negative Sentiment: The quarterly loss slightly exceeded expectations, while CVRx continues to report deeply negative profitability, including a negative net margin and negative return on equity. Analysts responded by downgrading the stock from “buy” to “hold,” reinforcing concerns about near-term growth and execution. CVRx Q2 2026 earnings call transcript

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.